Investments & Funding

Existing immunotherapies and checkpoint inhibitors have had limited success in combating this disease, highlighting the urgent need for new approaches.

This hospital complex will feature a fully equipped accident and emergency unit, oncology wards for cancer treatment, dialysis and high-dependency units for patients requiring intensive care, and a dedicated mother and child wing to improve maternal and child health outcomes.

The Greensboro plant spans 60,500 square feet (5,600 square meters) and supports both contract development and manufacturing organization (CDMO) services and packaging operations.

The new consolidated facility will have 265 beds and cover over 74,000 square meters.

Verve Therapeutics is developing innovative one-time gene editing therapies aimed at addressing the underlying causes of atherosclerotic cardiovascular disease (ASCVD).

Under the terms of the agreement, Supernus will pay US$8.50 per share in cash, amounting to an initial US$561 million for all outstanding shares of Sage.

The “Bupa Clinics” were established in collaboration with the Ministry of Health and Urgent Care Centers as part of Bupa Arabia’s social responsibility efforts.

Health Cabinet Secretary (CS) Hon. Aden Duale highlighted these efforts during a recent media briefing, emphasizing the government’s commitment to improving access to quality healthcare for all Kenyans.

This investment is part of its global €2 billion (US$2.32 billion) healthcare budget, with 25 percent allocated to Africa and the Middle East.